Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Melanoma 12Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 11Colorectal Neoplasms 9Triple Negative Breast Neoplasms 8Neoplasms 6Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Renal Cell 5Stomach Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 4Glioblastoma 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lung Neoplasms 2Liver Neoplasms 2Hematologic Diseases 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Advanced Solid Tumors 2Advanced Solid Tumor 2Adenocarcinoma 2von Hippel-Lindau Disease 1

Interventions

Paclitaxel 29Carboplatin 25Topotecan 12Gemcitabine 11Cyclophosphamide 11Cisplatin 11Taxes 10Filgrastim 9sargramostim 8pembrolizumab 8Docetaxel 8Bevacizumab 8Peripheral Blood Stem Cell Transplantation 6liposomal doxorubicin 5Flow Cytometry 5Interleukin-12 Subunit p35 4Drug Therapy 4fludarabine phosphate 3fludarabine 3Sirolimus 3Nivolumab 3Melphalan 3Immunohistochemistry 3Immunoenzyme Techniques 3Granulocyte-Macrophage Colony-Stimulating Factor 3Fulvestrant 3Etoposide 3Chemotherapy, Adjuvant 3Capecitabine 31-dodecylpyridoxal 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Ovarian Epithelial × spartalizumab × Clear all
NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Dana-Farber Cancer Institute

Phase 1 Terminated
33 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡